Table 3.
Overall and progression-free survival results by PDGFR copy number gain biomarker results.
| Patient Population | PDGFR copy number gain |
N | Median OS (mos) |
2-year OS rate |
5-year OS rate |
p-value | Median PFS (mos) |
2-year PFS rate |
5-year PFS rate |
p-value |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | Positive | 14 | 39.1 | 55% | n/a* | 0.82 | 10.1 | 46% | n/a* | 0.77 |
| Negative | 55 | 25.5 | 50% | 40% | 11.5 | 38% | 33% | |||
| Sarcomatoid | Positive | 12 | 14.3 | 55% | n/a* | 0.66 | 7.2 | 46% | n/a* | 0.58 |
| Negative | 24 | 25.9 | 50% | 40% | 9.7 | 38% | 33% | |||
| Control NSCLC | Positive | 2 | n/a* | 86% | 79% | 0.31 | n/a* | 77% | 69% | 0.3 |
| Negative | 31 | 22.4 | 96% | 85% | 12.1 | 93% | 76% |
*
no patients have died yet and a median survival results cannot be obtained